Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | DGKA | P23743 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744907 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL11857583 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL4346958 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL28070085 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL11865856 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL9244508 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL2428839 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL4334523 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL7208906 | 0.98 | TSHR (0.61) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL5098798 | 0.98 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4163106-A | Prostaglandin precursors and processes for preparing the same | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1979-07-31 | — | — | US | claimed |
| US-10407435-B2 | Diheteroaryl histone deacetylase inhibitors and their use in therapy | KARUS THERAPEUTICS LIMITED (GB) | 2019-09-10 | — | — | US | disclosed |
| US-20170313712-A1 | DIHETEROARYL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2017-11-02 | — | — | US | disclosed |
| EP-3212625-A1 | DIHETEROARYL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | Karus Therapeutics Ltd (GB) | 2017-09-06 | — | — | EP | disclosed |
| CN-107001340-A | Two heteroaryl histone deacetylase inhibitors and its therapeutical uses | 卡鲁斯治疗有限公司 | 2017-08-01 | — | — | CN | disclosed |
| WO-2016067040-A1 | DIHETEROARYL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LTD (GB) | 2016-05-06 | — | — | WO | disclosed |
| US-7985767-B2 | Glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; carboxy-functional amides or sulfonamide and carboxy bioisosteres thereof; 5-(-3-(N-(4-(1-hydroxyhexyl)phenyl)acetamido)butyl)thiophene-2-carboxylic acid for example | ALLERGAN, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080119539-A1 | THERAPEUTIC AMIDES | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
| US-4169199-A | Precursors for prostaglandin analogue and process for preparing the same | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1979-09-25 | — | — | US | disclosed |
| US-4163106-A | Prostaglandin precursors and processes for preparing the same | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1979-07-31 | — | — | US | disclosed |
| US-3996263-A | ANTIULCER | SANKYO COMPANY LIMITED (JA) | 1976-12-07 | — | — | US | disclosed |
| US-3993773-A | Control of mites with esters of cyclopropane substituted carboxylic acids | ZOECON CORPORATION (US) | 1976-11-23 | — | — | US | disclosed |
| US-3992412-A | 2α-(2-Carboxy-2-oxoethyl)-3β-hydroxy-5-oxo-1β-cyclopentaneheptanoic acid and process | MERCK & CO., INC. (US) | 1976-11-16 | — | — | US | disclosed |
| US-3992411-A | 2α-Formyl-3β-[(methoxalyl)oxy]-5-oxo-1β-cyclopentaneheptanoic acid and process | MERCK & CO., INC. (US) | 1976-11-16 | — | — | US | disclosed |
| US-3991083-A | 2α-(2-Loweralkanoyloxy-2-carboxyvinyl)-3β-hydroxy-5-oxo-1β-c | MERCK & CO., INC. (US) | 1976-11-09 | — | — | US | disclosed |
| US-3987087-A | ANTI-ULCER, NASAL PATENCY, WOUND HEALING, LABOR INDUCEMENT | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
| US-3983152-A | OXYTOCICS | SANKYO COMPANY LIMITED (JA) | 1976-09-28 | — | — | US | disclosed |
| US-3969384-A | Esters of cyclopropane alkanoic acids | ZOECON CORPORATION (US) | 1976-07-13 | — | — | US | disclosed |
| US-3960907-A | MITICIDES | ZOECON CORPORATION (US) | 1976-06-01 | — | — | US | disclosed |
| US-3954832-A | 16-And 16,16-methyl and ethyl substituted PGA1 -type compounds | THE UPJOHN COMPANY (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313712-A1 | DIHETEROARYL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | HDAC1, HDAC11, HDAC7 | TSHR 3353/4885LMNA 1428/4885ALDH1A1 1057/4885 |
| US-20080119539-A1 | THERAPEUTIC AMIDES | GOT2, GOT1, ARG2 | TSHR 2420/4885LMNA 3086/4885ALDH1A1 357/4885 |
| US-10407435-B2 | Diheteroaryl histone deacetylase inhibitors and their use in therapy | HDAC1, HDAC11, HDAC7 | TSHR 3353/4885LMNA 1428/4885ALDH1A1 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.